Privacy Policy
Signals Blog

Contributors

Categories

Update from the Clinic: March

. Welcome to your Update from the Clinic for the month of March. Investors weren’t so keen on Neuralstem’s topline results in amyotropic lateral sclerosis (ALS). NeoStem’s follow-up data from its PreSERVE study in acute myocardial infarction (AMI) was somewhat...

Right Turn: StemCellTalks in Tweets

. Last month (March 13), StemCellTalks held a symposium on diabetes and stem cell tourism to educate Toronto high school students about the field. (These events happen across Canada.) The morning session began with Dr. Elia Piccinini (University of Toronto) giving an...

Right Turn: End of an era, almost

> This is my final post as co-editor of Signals, and in sitting down to draft it, I found myself struggling to find words. How do you sum up six years of blogging? Quite simply, you don’t. However, as this also marks the end of the Stem Cell Network’s involvement...

Update from the Clinic: February

. Welcome to your Update from the Clinic for the month of February. Northwest Biotherapeutics received approval from Health Canada to proceed with its ongoing Phase 3 clinical study in Glioblastoma multiforme at clinical sites in Quebec. Sangamo and bluebird bio both...

Right Turn: No horsing around with this grand gesture

. American media and telecom billionaire John Malone, along with his horse-breeding wife Leslie, have generously donated U.S. $42.5 million to Colorado State University to launch the CSU Institute for Biologic Translational Therapies to develop regenerative medicine...

Grow your brains: Neural stem cells in 1 minute.

> Many of us only become acutely aware of our brain when it’s not working quite right. Like, say, if we have a migraine, or are diagnosed with a mental illness. Or we fall on the ice and give ourself a concussion that affects our vision, motor skills and...

Subscribe to Signals

Subscribe to our blog list to receive the latest news and updates.

You have Successfully Subscribed!